_256_384.jpg)
News | May 14, 2025
Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
The company has posted net profit of Rs. 158.71 crores for the Financial Year ended March 31, 2025
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
This approval authorizes the company to export Ibuprofen to the Chinese markets
Delivers robust earnings performance, successfully navigating a dynamic environment
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Bayer expects 2025 to be the most difficult year of its turnaround
Subscribe To Our Newsletter & Stay Updated
